Human Mesenchymal Stem Cells (hMSC) Market research report provides essential and knowledgeable insights on the market and details a descriptive account of the current scope and trend of the market following the global landscape.
Human Mesenchymal Stem Cells (hMSC) Market research report provides essential and knowledgeable insights on the market and details a descriptive account of the current scope and trend of the market following the global landscape.
CRANFORD - Citius Pharmaceuticals, Inc. ('Citius' or the 'Company') (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it has signed an exclusive agreement with Novellus Therapeutics Limited ('Novellus') to license iPSC-derived mesenchymal stem cells (iMSCs), and has created a new subsidiary, NoveCite, that will be focused on developing cellular therapies. NoveCite has a worldwide exclusive license from Novellus, an engineered cellular medicines company, to develop and commercialize NoveCite mesenchymal stem cells ('NC-iMSCs') to treat acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome ('ARDS') associated with COVID-19
Reviewed by Emily Henderson, B.Sc.Oct 12 2020 By far, the most common injuries seen in emergency rooms in the United States are those affecting extremities.
The mere mention of a coronavirus vaccine has created incredible interest in names like Sorrento Therapeutics (NASDAQ:SRNE).After all, if a company can get a vaccine to market, businesses and schools may be able to fully reopen.
This article was originally published here World J Stem Cells. 2020 Sep 26;12(9):1013-1022.
Mesenchymal Stem Cells Market Report Delivering Growth Analysis with Key Trends of Top Companies (2020-2026) A comprehensive research study on the Mesenchymal Stem Cells Marketwas recently published by Market Report Expert. This is an up-to-date report, covering the current COVID-19 impact on the market. The Coronavirus (COVID-19) has affected every aspect of life globally and thus altering the global market scenario
Citius Pharmaceuticals (NASDAQ:CTXR) has exercised its previously announced option agreement, andannounced an exclusive agreement with Novellus Therapeutics to license iPSC-derived mesenchymal stem cells (iMSCs). The company has created a new subsidiary, NoveCite, that will focus on development and commercialization of NoveCite mesenchymal stem cells (NC-iMSCs) for the treatment of acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19.
Advances in the stem cell therapy sector have been phenomenal over the years. Its assistance in curing humans of various diseases and disorders has generated expansive advancements. These advancements are not just limited to humans
CRANFORD, N.J., Oct.
HOUSTON, Oct. 1, 2020 /PRNewswire/ -- FibroGenesis, the leading developer of fibroblast based therapeutic solutions for unmet medical needs has entered into a clinical collaboration agreement with Brazilian R4D Biotech.Holding the world's largest patent portfolio in the field of cell therapies using fibroblasts, FibroGenesis is expanding its ongoing clinical programs internationally. The partnership will pave the way for clinical studies of PneumoBlast in Brazil as a unique treatment of acute respiratory distress syndrome (ARDS) for patients affected by COVID-19, in parallel to clinical studies in the United States upon approval by the FDA
Recent Comments